B. Hiddinga

发表

MA12.06 STELLAR – Final Results of a Phase 2 Trial of TTFields with Chemotherapy for First-Line Treatment of Malignant Pleural Mesothelioma

A. Chella, L. Crinò, G. Ceresoli, 2018, Journal of Thoracic Oncology.

Hestia criteria can safely select patients with pulmonary embolism for outpatient treatment irrespective of right ventricular function

B. Hiddinga, L. Kroft, M. Huisman, 2013, Journal of thrombosis and haemostasis : JTH.

Addressing the Palliative Setting in Advanced Lung Cancer Should Not Remain a Barrier: A Multicenter Study

J. V. van Meerbeeck, B. Hiddinga, A. Janssens, 2017, Clinical lung cancer.

Surgery in mesothelioma--where do we go after MARS?

J. V. van Meerbeeck, B. Hiddinga, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Recent developments in the treatment of small cell lung cancer

J. V. van Meerbeeck, B. Hiddinga, P. Pauwels, 2021, European Respiratory Review.

Small-Cell Lung Cancer: Is the Black Box Finally Opening Up?

K. Kok, B. Hiddinga, 2021, Cancers.

Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?

J. V. van Meerbeeck, B. Hiddinga, P. Pauwels, 2022, Oncotarget.

Hestia criteria can discriminate high- from low-risk patients with pulmonary embolism

B. Hiddinga, M. Huisman, H. Hofstee, 2012, European Respiratory Journal.

Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody.

J. V. van Meerbeeck, B. Hiddinga, P. Cras, 2017, Lung cancer.

Abstract 4067: PD-L1 expression, CD8 cells and MHC-class-1 Beta-2-microglobulin expression in advanced non-small lung cancer

H. Groen, B. Hiddinga, W. Timens, 2019, Immunology.

O6-Methylguanine-DNA methyltransferase (MGMT): A drugable target in lung cancer?

J. V. van Meerbeeck, B. Hiddinga, P. Pauwels, 2017, Lung cancer.

Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors

H. Groen, E. Schuuring, B. Hiddinga, 2021, Molecular oncology.

Second line therapy in malignant pleural mesothelioma: A systematic review.

J. V. van Meerbeeck, B. Hiddinga, P. Baas, 2015, Lung cancer.

Imaging of urgencies and emergencies in the lung cancer patient

P. Parizel, J. V. van Meerbeeck, B. Hiddinga, 2018, Insights into Imaging.

Bevacizumab in pleural mesothelioma: too few, too late?

B. Hiddinga, J. Meerbeeck, 2016 .

Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period

P. V. Van Schil, J. V. van Meerbeeck, B. Hiddinga, 2017, Acta chirurgica Belgica.

Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial.

H. Groen, B. Hiddinga, R. Wijsman, 2023, Lung cancer.

Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature.

H. Groen, E. Schuuring, B. Hiddinga, 2021, Clinical lung cancer.

Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles.

H. Groen, E. Schuuring, B. Hiddinga, 2020, JCO precision oncology.

MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): a statistical analysis plan

J. Maessen, P. V. Van Schil, J. Annema, 2021, Trials.

MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): study protocol of a multicenter randomised controlled trial

J. Maessen, P. V. Van Schil, J. Annema, 2018, BMC Surgery.

MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy ( MEDIASTrial ) MEDIASTrial

J. Maessen, J. Annema, B. Hiddinga, 2018 .

Monitoring EGFR TKI resistance in real time using ddPCR-based liquid biopsy: a case report

J. V. van Meerbeeck, B. Hiddinga, P. Pauwels, 2018, Journal of Clinical Pathology.

The additional diagnostic value of virtual bronchoscopy navigation in patients with pulmonary nodules - The NAVIGATOR study.

R. Vliegenthart, D. Slebos, B. Hiddinga, 2023, Lung cancer.

Mesothelioma treatment: Are we on target? A review

J. V. van Meerbeeck, B. Hiddinga, C. Rolfo, 2014, Journal of advanced research.

Illness understanding in patients with advanced lung cancer: curse or blessing?

J. V. van Meerbeeck, B. Hiddinga, A. Janssens, 2016, Annals of palliative medicine.

Non‐small‐cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy

E. Schuuring, B. Hiddinga, J. Kluiver, 2021, Histopathology.

High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.

B. Hiddinga, C. H. van der Leest, A. Dingemans, 2022, Lung cancer.

Hestia criteria can safely select patients with pulmonary embolism for outpatient treatment irrespective of right ventricular function

B. Hiddinga, H. Hofstee, L. Faber, 2013, Journal of thrombosis and haemostasis : JTH.

O6-Methylguanine-DNA methyltransferase (MGMT): A drugable target in lung cancer?

J. V. van Meerbeeck, B. Hiddinga, P. Pauwels, 2017, Lung cancer.

Response to immune checkpoint inhibition is associated with the gut microbiome in advanced KRAS-mutated non-small cell lung cancer

B. Hiddinga, R. Weersma, R. Gacesa, 2023, medRxiv.